EUVIMEDEUVIMED entdecken
Crossref

Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia

Nicolas Lecornec iD, Florence Rabian iD, Marie-Emilie Dourthe, Florian Chevillon, Karima Yakouben, Delphine Chaillou, Sophie Caillat-Zucman, Alexis Cuffel, Emmanuelle Lesprit, Anne Arnould, Jérôme Naudin, Julie Roupret-Serzec und 16 weitere

Leukemia · 2026

DOI: 10.1038/s41375-026-02867-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2026. Verfasst von Nicolas Lecornec und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Immunotherapy, Adoptive, Neoplasm Recurrence, Local. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tisagenlecleucel (tisa-cel), an autologous anti-CD19 CAR T-cell therapy, has significantly improved outcomes in pediatric, adolescents and young adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). However, 30-50% experience early failure or relapse. We retrospectively analyzed 52 cases of early failures (n = 13) or relapses (n = 39), evaluating post-tisa-cel outcomes and prognostic factors. CD19 antigen loss was the only factor associated with a lower complete remission rate after salvage therapy (OR = 0.16, 95%CI [0.03-0.90], p = 0.04). Median overall survival (OS) was 14.5 months, with a 2-year OS of 37.4% (95%CI [24.4-50.4]), similar between early failure (38.5%) and relapse (37.0%) groups (p = 0.78). Patients with measurable residual disease only at salvage initiation had significantly improved 2-year OS (61.9%, (95%CI [38.1-78.8])) compared to those with overt disease (20.7%, (95%CI [8.4-36.7], p = 0.008)). Factors associated with inferior OS included high pre-infusion tumor burden (HR = 3.57, p < 0.01), and prior inotuzumab ozogamicin exposure (HR = 3.81, p < 0.01). Although salvage therapies and hematopoietic stem cell transplantation benefit some patients, 5 of 18 transplanted patients died from treatment-related toxicity, underscoring the significant associated risks. These findings highlight the poor prognosis of tisa-cel failures and the urgent need for novel strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaImmunotherapy, AdoptiveNeoplasm Recurrence, LocalHumansAdolescentFemaleChildRetrospective StudiesMaleYoung AdultPrognosisSalvage TherapyChild, PreschoolAdultSurvival RateFollow-Up StudiesAntigens, CD19

Substanzen

tisagenlecleucelReceptors, Antigen, T-CellAntigens, CD19

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Immunology, Hôpital Universitaire Robert Debré, AP-HP and Université Paris Cité, Paris, France.
  • Adolescents and Young Adults Unit, Hôpital Universitaire Saint Louis, AP-HP and Université Paris Cité, Paris, France.
  • Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, AP-HP and Université́ Paris Cité, Institut Necker-Enfants Malades (INEM), INSERM U1151, Paris, France.
  • Laboratory of Immunology, Hôpital Universitaire Saint Louis, AP-HP and INSERM UMR1149, Université́ Paris Cité, Paris, France.
  • Etablissement Français du Sang, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.
  • Pediatric Intensive Care Unit, Hôpital Universitaire Robert Debré́, AP-HP and Université Paris Cité, Paris, France.

ORCID-Profile: Nicolas Lecornec, Florence Rabian, Aurélie Caye-Eude, Rathana Kim, Jean-Hugues Dalle, André Baruchel, Nicolas Boissel

Zitieren

APA

Lecornec, N., Rabian, F., Dourthe, M. E., Chevillon, F., Yakouben, K., Chaillou, D., Caillat-Zucman, S., Cuffel, A., Lesprit, E., Arnould, A., Naudin, J., Roupret-Serzec, J., Parquet, N., Brignier, A., Guérin-El Khourouj, V., Lainey, E., Caye-Eude, A., Arfeuille, C., Clappier, E., …, & Boissel, N. (2026). Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. https://doi.org/10.1038/s41375-026-02867-9

Vancouver

Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, et al. Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2026. doi:10.1038/s41375-026-02867-9

BibTeX
@article{Lecornec2026,
  author = {Lecornec, Nicolas and Rabian, Florence and Dourthe, Marie-Emilie and Chevillon, Florian and Yakouben, Karima and Chaillou, Delphine and Caillat-Zucman, Sophie and Cuffel, Alexis and Lesprit, Emmanuelle and Arnould, Anne and Naudin, Jérôme and Roupret-Serzec, Julie and Parquet, Nathalie and Brignier, Anne and Guérin-El Khourouj, Valérie and Lainey, Elodie and Caye-Eude, Aurélie and Arfeuille, Chloé and Clappier, Emmanuelle and Kim, Rathana and Mathis, Stéphanie and Chaix, Marie-Laure and Azoulay, Elie and Dalle, Jean-Hugues and Madelaine, Isabelle and Larghero, Jérôme and Baruchel, André and Boissel, Nicolas},
  title = {Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia},
  journal = {Leukemia},
  year = {2026},
  doi = {10.1038/s41375-026-02867-9}
}
Kostenlos starten →